Corner offices at Ardsley are very busy. Lots of calls Lots of interest Data room populated and already being canvas diligently by the competing teams Offers are coming soon Expecting UCB to come in at around 33.40/share; plus, they are ready to fight off any contenders. Excellent synergies for Inbrija in their Parkinson's Disease Franchise. Although Biogen could manage Chelsea much easier, and possibly create inhaled biologics. There are also others in the perifery. SK lifesciences ?
Then why would Mr. D Lawrence not wait to sell 31,000 shares now leaving less than 6,000 shares on the table?
You really don't understand the concept of stock options - these had a 10 year expiration and thus little choice but to execute them and get whatever cash gains were there. Otherwise, the options will expire, and he gets nothing. Relax We all will be well taken care of Whether there is a Merger or not. ACOR will hit the mid to high 30s in the next few weeks.
The trolls trolls are trying to change the narrative once again by spreading alternative facts of Acorda's successful diverse management team Let us re-focus to the rising ACOR share price that we have seen over the past 2 weeks. Bravo RC !!!
